Literature DB >> 1906502

IL-10: a novel cytotoxic T cell differentiation factor.

W F Chen1, A Zlotnik.   

Abstract

A previous report concluded that a new cytokine, designated IL-10, is a growth cofactor for thymocytes, spleen, and lymph node cells. In this report, we have focused on the effects of IL-10 on CD8+ spleen T cells. We first observed that IL-10 enhances the growth of CD8+ T cells to IL-2. We then investigated the effect of murine rIL-10 on the induction of murine effector CTL from CTL precursors (CTL-p) using both bulk and filler cell-free limiting-dilution cultures. IL-10 alone could not induce Con A-activated FACS-sorted CD8+ T cells either to proliferate or to generate effector CTL. In combination with IL-2, however, IL-10 augmented the cytolytic activity of effector CTL generated from Con A-activated spleen CD8+ T cells in bulk cultures incubated for 5 days. In limiting-dilution cultures (using solid-phase anti-CD3 mAb as stimulus), IL-10, in combination with IL-2, substantially increased the CTL-p frequency and augmented the cytolytic activity per clone expanded from one CD8+ T cell when compared with cells cultured in IL-2 alone. Kinetic studies showed that IL-10 is required at both early and late culture stages for optimal generation of effector CTL. The potentiating effects of IL-10 on CTL function were neutralized by an anti-IL-10 mAb. These results indicate that IL-10 has direct effects on mature T cells, and suggest that IL-10 also functions as a cytotoxic T cell differentiation factor, which promotes a higher number of IL-2-activated CTL-p to proliferate and differentiate into effector CTL. In contrast, IL-10 did not enhance significantly the lymphokine-activated killer cell activity of IL-2-grown CD8+ cytotoxic T cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1906502

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  80 in total

1.  IL-10 enhances IL-2-induced proliferation and cytotoxicity by human intestinal lymphocytes.

Authors:  E C Ebert
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

Review 2.  Th1/Th2 balance in cancer, transplantation and pregnancy.

Authors:  M R Shurin; L Lu; P Kalinski; A M Stewart-Akers; M T Lotze
Journal:  Springer Semin Immunopathol       Date:  1999

Review 3.  Type I (insulin-dependent) diabetes is a Th1- and Th2-mediated autoimmune disease.

Authors:  S T Azar; H Tamim; H N Beyhum; M Z Habbal; W Y Almawi
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

4.  IL-10-induced gp130 expression in mouse mast cells permits IL-6 trans-signaling.

Authors:  Daniel Traum; Patricia Timothee; Jonathan Silver; Stefan Rose-John; Matthias Ernst; David F LaRosa
Journal:  J Leukoc Biol       Date:  2011-12-02       Impact factor: 4.962

Review 5.  Biological properties of interleukin 10.

Authors:  M Howard; A O'Garra; H Ishida; R de Waal Malefyt; J de Vries
Journal:  J Clin Immunol       Date:  1992-07       Impact factor: 8.317

6.  Interleukin-10 ablation promotes tumor development, growth, and metastasis.

Authors:  Takashi Tanikawa; Cailin Moira Wilke; Ilona Kryczek; Grace Y Chen; John Kao; Gabriel Núñez; Weiping Zou
Journal:  Cancer Res       Date:  2011-11-28       Impact factor: 12.701

7.  Interleukin-10 (IL-10) augments allograft arterial disease: paradoxical effects of IL-10 in vivo.

Authors:  Y Furukawa; G Becker; J L Stinn; K Shimizu; P Libby; R N Mitchell
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

8.  Production of interleukin-10 by human bronchogenic carcinoma.

Authors:  D R Smith; S L Kunkel; M D Burdick; C A Wilke; M B Orringer; R I Whyte; R M Strieter
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

9.  Functional regions of the mouse interleukin-10 receptor cytoplasmic domain.

Authors:  A S Ho; S H Wei; A L Mui; A Miyajima; K W Moore
Journal:  Mol Cell Biol       Date:  1995-09       Impact factor: 4.272

10.  Requirements for activation of CD8+ murine T cells. I. Development of cytolytic activity.

Authors:  D C Cronin; D W Lancki; F W Fitch
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.